Ezetimibe

“And we could, without getting into the nuances of it, there was a huge debate as to whether anyone should ever receive Zetia and monotherapy. And it was viewed as not an evidence-based approach because it didn't have the hard outcome trial that said, if you give Zetia in monotherapy, you will save lives.”

“And I think there's still a lot of pushback to that approach. And I would argue that what you've pointed out is another example of that, which is to say, on average, giving Zetia as monotherapy probably doesn't save lives. But if you could target the people who are super responders.”

“It's not clinically significant. But that means you're going to be tolerating patients on Crestor and Zetia walking around with AST and ALT of 80. Right, right. And the reality of it is, I just have a hard time believing that that makes sense.”

“Explain something to me. So if you go and buy branded Zetia today, it's not that expensive. If you go and buy branded Nexlitol, I mean, it's as expensive as an injectable monoclonal antibody.”

“Ezetimibe is a drug that really works outside the body, so to speak, right? It works in the gut. It blocks the Niemann-Pick C1-like-1 transporter.”

“You could probably pull it out of a biobank for an existing study that was already done on Ezetimibe. So we could at least get the suggestion of that from such a study, because we do have at least one.”

“I take statins, I take Ezetimibe you know so various interventions where there's very credible evidence.”